ERBB2 and breast carcinoma: In the KATHERINE trial, high-risk HER2+ breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and HER2-targeted therapy were randomized to adjuvant T-DM1 versus trastuzumab.